MedTrace Logo

Expanded Access Program for RP in Adults

NCT06574997 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-04-13

No results posted yet for this study

Summary

This intermediate-size patient population expanded access program is to provide access to investigational product OCU400 for up to 75 patients with Retinitis Pigmentosa (RP) outside of the ongoing clinical trial Phase 3 program for patients who do not have access to alternative Food and Drug Administration (FDA)-approved products for treatment of the disease.

Conditions

Interventions

DRUG

OCU400

Participants will receive a subretinal injection of OCU400 modifier gene therapy product.

Sponsors & Collaborators

Principal Investigators

  • Huma Qamar, MD, MPH, CMI · Ocugen

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06574997 on ClinicalTrials.gov